
Emma Van Hook Emma Van Hook is a director of Policy & Research at PhRMA focusing on the promise of the biopharmaceutical pipeline, the value of medicines, the R&D process, and personalized medicine.
Recent Posts
ICYMI – Survey underscores daily burden of migraines

A new survey reveals the painful and disruptive reality of migraine for many patients, with many patients living with pain for nearly half of every month. The survey paints a picture of the extensive...
Read More
Record number of personalized medicines approved in 2017

We are in an exciting time in biomedical innovation, as rapid scientific and technological advances are leading to new ways of preventing, diagnosing, and treating disease. Nothing illustrates the...
Read More
Innovation comes in many forms, including new and expanded uses of existing medicines

2017 was a record-breaking year for new drug approvals, with the U.S. Food and Drug Administration (FDA) approving 56 new drugs and biologics. But the innovation did not stop there. As the FDA...
Read More
Driving innovation through collaboration

A new report from Deloitte examines the changing landscape of biopharmaceutical research, as stakeholders across the R&D ecosystem are increasingly coming together to tackle sciences’ most vexing...
Read More
Working together to combat global Zika threat

The Zika virus is top of mind as the 2016 Summer Olympic Games get underway tomorrow in Rio. While once thought to be confined to limited areas of Africa, Southeast Asia and the Pacific Islands, the...
Read More
New report: Decade of breakthroughs in cancer

The pace of science is yielding remarkable innovation for cancer patients as we learn more about the underlying factors driving the spread and growth of cancer. These advances are opening new doors...
Read More
2015: A banner year for personalized medicine

2015 was a record year for personalized medicine approvals, according to a new analysis from the Personalized Medicine Coalition (PMC). This news confirms the growing role of personalized medicine...
Read More
5 Things You Didn’t Know about Researching and Developing a New Medicine

Unless you work in biopharmaceutical research and development (R&D), chances are the process of developing new medicines seems like a black box. It is hard to imagine how researchers go from an...
Read More
ICYMI: New Report on Benefits of Cancer Medicines That Emerge After FDA Approval

In case you missed it, Boston Healthcare Associates recently published a report examining how additional benefits of cancer medicines emerge over time through ongoing research after initial approval...
Read More
ICYMI: The Importance of Enrolling in Clinical Trials

Clinical trials are a crucial step in the long and costly process of researching and developing a new medicine to address substantial unmet medical needs in such areas as Alzheimer’s, cancer, and...
Read More